Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: Immunohistochemistry results

被引：3
|
作者：
Yang, S. X.
Kummar, S.
Rubinstein, L.
Gutierrez, M.
Murgo, A. J.
Parchment, R. E.
Nguyen, D.
Chen, A. P.
Tomaszewski, J. E.
Doroshow, J. H.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] SAIC Inc, Frederick, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3580
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma
    Paterniti, Irene
    Scuderi, Sarah Adriana
    Casili, Giovanna
    Lanza, Marika
    Mare, Marzia
    Giuffrida, Raffella
    Colarossi, Cristina
    Portelli, Marco
    Cuzzocrea, Salvatore
    Esposito, Emanuela
    BIOMEDICINES, 2021, 9 (07)
  • [42] Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase
    Parise, Robert A.
    Shawaqfeh, Mohammad
    Egorin, Merrill J.
    Beumer, Jan H.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 872 (1-2): : 141 - 147
  • [43] A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
    Hendrickson, Andrea E. Wahner
    Menefee, Michael E.
    Hartmann, Lynn C.
    Long, Harry J.
    Northfelt, Donald W.
    Reid, Joel M.
    Boakye-Agyeman, Felix
    Kayode, Olumide
    Flatten, Karen S.
    Harrell, Maria I.
    Swisher, Elizabeth M.
    Poirer, Guy G.
    Satele, Daniel
    Allred, Jake
    Lensing, Janet L.
    Chen, Alice
    Ji, Jiuping
    Zang, Yiping
    Erlichman, Charles
    Haluska, Paul
    Kaufmann, Scott H.
    CLINICAL CANCER RESEARCH, 2018, 24 (04) : 744 - 752
  • [44] Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
    Plummer, Ruth
    Jones, Christopher
    Middleton, Mark
    Wilson, Richard
    Evans, Jeffrey
    Olsen, Anna
    Curtin, Nicola
    Boddy, Alan
    McHugh, Peter
    Newell, David
    Harris, Adrian
    Johnson, Patrick
    Steinfeldt, Heidi
    Dewji, Raz
    Wang, Diane
    Robson, Lesley
    Calvert, Hilary
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7917 - 7923
  • [45] A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors
    Gao, Bo
    Voskoboynik, Mark
    Cooper, Adam
    Wilkinson, Kate
    Hoon, Siao
    Hsieh, Chih-Yi
    Cai, Suixiong
    Tian, Ye Edward
    Bao, Jun
    Ma, Ning
    Wang, Chen
    Zhang, Ming
    Li, Baoyue
    Guo, Mingchuan
    Zhou, Ruiyu
    Wang, Xiaozhu
    Xu, Cong
    de Souza, Paul
    CANCER, 2023, 129 (07) : 1041 - 1050
  • [46] A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.
    Hendrickson, Andrea Elisabeth Wahner
    Menefee, Michael E.
    Hartmann, Lynn C.
    Long, Harry J.
    Northfelt, Donald W.
    Reid, Joel M.
    Boakye-Agyeman, Fleix
    Flatten, Karen S.
    Poirier, Guy G.
    Lensing, Janet
    Erlichman, Charles
    Kaufmann, Scott H.
    Haluska, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Preclinical evaluation of Poly (ADP) Ribose Polymerase (PARP) enzyme inhibitor, ABT-888, in combination with cytotoxic agents in small cell lung cancer (SCLC)
    Owonikoko, Taofeek K.
    Zhang, Guojing
    Yue, Ping
    Ramalingam, Suresh
    Khuri, Fadlo
    Sun, Shi-Yong
    CANCER RESEARCH, 2011, 71
  • [48] Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP
    Kummar, Shivaani
    Rubinstein, Larry
    Kinders, Robert
    Ji, Jiuping
    Parchment, Ralph
    Gutierrez, Martin
    Murgo, Anthony
    Chen, Alice
    Khin, Sonny
    Zhang, Yiping
    Simmons, Dwight
    Yancey, Mary Ann
    Allen, Deborah
    Horneffer, Yvonne
    Juwara, Lamin
    Chang, Richard
    Gordon, Gary
    Tomaszewski, Joseph
    Doroshow, James
    CANCER RESEARCH, 2009, 69
  • [49] Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
    Horton, Terzah M.
    Jenkins, Gaye
    Pati, Debananda
    Zhang, Linna
    Dolan, M. Eileen
    Ribes-Zamora, Albert
    Bertuch, Alison A.
    Blaney, Susan M.
    Delaney, Shannon L.
    Hegde, Madhuri
    Berg, Stacey L.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (08) : 2232 - 2242
  • [50] Role of ABT888, a Novel Poly(ADP-Ribose) Polymerase (PARP) Inhibitor in Countering Autophagy and Apoptotic Processes Associated to Spinal Cord Injury
    Casili, Giovanna
    Campolo, Michela
    Lanza, Marika
    Filippone, Alessia
    Scuderi, Sarah
    Messina, Salvatore
    Ardizzone, Alessio
    Esposito, Emanuela
    Paterniti, Irene
    MOLECULAR NEUROBIOLOGY, 2020, 57 (11) : 4394 - 4407
12345